<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168805</url>
  </required_header>
  <id_info>
    <org_study_id>1160.25</org_study_id>
    <secondary_id>2004-001317-34</secondary_id>
    <nct_id>NCT00168805</nct_id>
  </id_info>
  <brief_title>RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery</brief_title>
  <official_title>RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      A phase III, randomised, parallel-group, double-blind, active controlled study to investigate
      the ef ficacy and safety of two different dose regimens of orally administered dabigatran
      etexilate capsule s [150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) on
      the day of surgery] comp ared to subcutaneous enoxaparin 40 mg once daily for 6 to 10 days,
      in prevention of venous thromboem bolism in patients with primary elective total knee
      replacement surgery. RE-MODEL (Thromboembolism prevention after knee surgery)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>All cause death, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</measure>
    <time_frame>3 months</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</measure>
    <time_frame>First administration until 6-10 days</time_frame>
    <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Volume of blood loss for treated and operated patients during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>First administration to end of study</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2101</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate 220 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>220 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>40 mg once daily</description>
    <arm_group_label>enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>150 mg once daily</description>
    <arm_group_label>dabigatran etexilate 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>220 mg once daily</description>
    <arm_group_label>dabigatran etexilate 220 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Inclusion criteria (selected):

          -  Patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive
             total knee replacement

          -  Written Informed Consent

        Exclusion criteria

        Exclusion criteria (selected):

          -  Patients with an excessive risk of bleeding, for example because of history of
             bleeding diathesis major surgery or trauma within the last 3 months history of
             haemorrhagic stroke or any of the following intracranial pathologies: bleeding,
             neoplasm, arteriovenous (AV) malformation or aneurysm clinically relevant bleeding or
             gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within
             7 days prior to joint replacement surgery or anticipated need during the study
             treatment period thrombocytopenia.

          -  Active malignant disease or current cytostatic treatment

          -  Known severe renal insufficiency

          -  Liver disease expected to have any potential impact on survival, or elevated aspartate
             aminotransferase (AST) or alanine transaminase (ALT) &gt; 2x upper limit of normal

          -  Recent unstable cardiovascular disease or history of myocardial infarction within the
             last 3 months

          -  Pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial
             and are not practising or do not plan to continue practising acceptable me thods of
             birth control

          -  Allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced
             thrombocytopenia) or dabigatran

          -  Contraindications to enoxaparin

          -  Participation in a clinical trial during the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.25.06108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garren</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.06111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wr. Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03207 UVC Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03209 ZOL St. Jan</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03206 Campus Sint-Lucas</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03208 UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03202 Virga Jesseziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03203 AZ Sint Elisabeth</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03205 Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Lanaken</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03201 UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno-Bohunice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pradubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04571 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04570 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04573 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04574 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København S</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04575 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poitiers cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roubaix cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soyaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04906 Caritaskrankenhaus</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04910 F.-A.-Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04904 Orthopädische Universitätsklinik</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04902 Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04911 Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04912 Orthopädische Klinik Markgröningen gGmbH</name>
      <address>
        <city>Markgröningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04901 Kreiskrankenhaus</name>
      <address>
        <city>Rheinfelden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04903 Hellmuth-Ulrici-Kliniken</name>
      <address>
        <city>Sommerfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04905 Aukammklinik</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.02701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.02703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.02702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcorcón (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Móstoles (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.03410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Falköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kungälv</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.25.04609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2010</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The treatment period is from first administration of study medication, until 3 days after last administration of study medication. Treatment duration is planned for 8 days. The study period is from first administration of study medication until day 84 - 91.</recruitment_details>
      <pre_assignment_details>Whilst 2101 patients were enrolled/randomised to treatment prior to surgery in this trial, only 2076 started treatment. Therefore, 25 patients were randomised but not treated (treatment was planned to start post surgery).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="P3">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="679"/>
                <participants group_id="P2" count="703"/>
                <participants group_id="P3" count="694"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="608"/>
                <participants group_id="P2" count="625"/>
                <participants group_id="P3" count="616"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="679"/>
                <participants group_id="P2" count="703"/>
                <participants group_id="P3" count="694"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="630"/>
                <participants group_id="P2" count="647"/>
                <participants group_id="P3" count="632"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B3">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="679"/>
            <count group_id="B2" value="703"/>
            <count group_id="B3" value="694"/>
            <count group_id="B4" value="2076"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="9.0"/>
                    <measurement group_id="B2" value="67.5" spread="8.8"/>
                    <measurement group_id="B3" value="68.3" spread="8.8"/>
                    <measurement group_id="B4" value="67.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="478"/>
                    <measurement group_id="B4" value="1370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index N=(677;702;692;2071)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="4.9"/>
                    <measurement group_id="B2" value="30.1" spread="5.0"/>
                    <measurement group_id="B3" value="29.8" spread="4.9"/>
                    <measurement group_id="B4" value="29.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
          <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 9.2%. This results from the null-hypotheses of non-inferiority testing, where the absolute risk difference has to be below 9.2%. Non-inferiority can only be shown with CI.</non_inferiority_desc>
            <p_value>0.6648</p_value>
            <p_value_desc>p-value is for superiority testing</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 9.2%. This results from the null-hypotheses of non-inferiority testing, where the absolute risk difference has to be below 9.2%. Non-inferiority can only be shown with CI.</non_inferiority_desc>
            <p_value>0.3553</p_value>
            <p_value_desc>p-value is for superiority testing</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
        <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
          <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="527"/>
                <count group_id="O3" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3760</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8151</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
        <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
          <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="525"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4715</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9325</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
        <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
          <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="211"/>
                    <measurement group_id="O3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6463</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3740</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
        <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - op (all patients who are treated and operated)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
          <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who are treated and operated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="696"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0385</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1414</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
        <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - op</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
          <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="696"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died During Treatment Period</title>
        <description>All cause death, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Full Analysis Set - op</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During Treatment Period</title>
          <description>All cause death, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="696"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
        <time_frame>3 months</time_frame>
        <population>Patients with any data available during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
          <population>Patients with any data available during follow-up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="658"/>
                <count group_id="O2" value="679"/>
                <count group_id="O3" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total VTE and all-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asymptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>symptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
        <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>First administration until 6-10 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
          <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="679"/>
                <count group_id="O2" value="703"/>
                <count group_id="O3" value="694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569"/>
                    <measurement group_id="O2" value="587"/>
                    <measurement group_id="O3" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8209</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfusion</title>
        <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
                <count group_id="O2" value="696"/>
                <count group_id="O3" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with &gt;=1 transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="253"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with &gt;=1 non-autologous transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss</title>
        <description>Volume of blood loss for treated and operated patients during surgery.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss</title>
          <description>Volume of blood loss for treated and operated patients during surgery.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="669"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="258"/>
                    <measurement group_id="O2" value="190" spread="250"/>
                    <measurement group_id="O3" value="191" spread="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities.</description>
        <time_frame>First administration to end of study</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities.</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="621"/>
                <count group_id="O2" value="645"/>
                <count group_id="O3" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase N=(620;645;636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease N=(620;645;636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase N=(621;645;637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease N=(621;645;637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase N=(619;644;635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease N=(619;644;635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration to end of study</time_frame>
      <desc>Treatment emergent events (last medication + 3 days)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="E3">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobilisation prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="405" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="438" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="426" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

